GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT01469351

CompletedPhase NA

Identifying Potential Effects of Liraglutide on Degenerative Changes

Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes

Lead sponsor

University of Aarhus

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Alzheimer's / cognition

Key I/E criterion

—

Primary endpoint

•PIB PET scan

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01469351

Org study ID2011-000794-31

Timeline

Milestones

Study first posted2011-11-10estimated

Last update posted2013-04-19estimated

Study start2012-01 (month precision)

Primary completion2013-04actual (month precision)

Study completion2013-04actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Alzheimer's / cognition

Eligibility

Who can enroll

Minimum age50 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Informed consent before study-related activity

•Adult competent persons

•Diagnosed with diagnosed Alzheimer's disease. With a MMSE score between 18-21 the diagnosis should be entirely based on the clinic, while diagnosis by MMSE with a score > 22 should be diagnosed by spinal puncture

•Age ≥ 50 years and ≤ 80 years

•Caucasians

Exclusion criteria

•Diabetes mellitus

•Clinically significant liver (s-ALT > 2 times upper reference or creatinine-clearance < 30 mL / min, assessed on Cockcroft-Gault normogram)

•Clinically significant anemia

•Other clinically relevant abnormal biochemical value

•Current or former presence of one of the following diseases with clinical relevance:

1. another CNS-illness other than diagnosed depression treated with SSRI or SSRI similar drugs.

2. liver disease

3. kidney disease

4. endocrinological disease other than well controlled hypothyroidism

•Current or history of chronic or acute pancreatitis

•Any disease which the investigators believe may affect the study

•Patients treated with TCA or neuroleptics

•Known abuse of alcohol or drugs

•Known allergy to liraglutide or any of the other components (disodium phosphate dihydrate, propylene glycol and phenol)

•Participation in a clinical trial less than 3 months before inclusion in this study

•Persons who within a period of the last 2 years have participated in scientific experiments involving the use of isotopes, or who have had greater diagnostic tests performed using applied ionizing radiation

•If patients are treated with SSRI or SSRI similar drugs or antihypertensives this treatment should be stable

•Claustrophobia or other missing cooperation

•Severe overweight > 130kg

•Ferro-magnetic prosthesis, pacemaker or other metals incorporated in the body

•Significant abnormities in the brain detected by MR scanning

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Other (unclassified)

Other clinical outcomes

2 endpoints

Primary/protocol endpoint/low confidence

PIB PET scan

Time frame:PIB PET-scan at baseline and after 26 weeks

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Neuro-psychological tests

Time frame:At baseline, after 12 weeks and after 26 weeks

descriptive, improvement

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

FDG PET Scan

Time frame:FDG PET-scan at baseline and after 26 weeks

change from baseline, descriptive

Publications (7)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes.
Trends in endocrinology and metabolism: TEM2017 Feb (month)PMID27871675doi:10.1016/j.tem.2016.10.001via clinicaltrials gov reference derived + pubmed nct search
In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Frontiers in aging neuroscience2016 (year)PMID27252647doi:10.3389/fnagi.2016.00108via clinicaltrials gov reference derived + pubmed nct search
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
Danish medical journal2012 Oct (month)PMID23158895via clinicaltrials gov reference derived + pubmed nct search
Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.
Behavioural brain research2009 Dec 14PMID19573562doi:10.1016/j.bbr.2009.06.035via CT.gov background
Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment.
Current Alzheimer research2009 Jun (month)PMID19519314doi:10.2174/156720509788486563via CT.gov background
Molecular connexions between dementia and diabetes.
Neuroscience and biobehavioral reviews2007 (year)PMID17544131doi:10.1016/j.neubiorev.2007.04.004via CT.gov background
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Nature medicine2003 Sep (month)PMID12925848doi:10.1038/nm919via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.